NO942241L - - Google Patents

Info

Publication number
NO942241L
NO942241L NO942241A NO942241A NO942241L NO 942241 L NO942241 L NO 942241L NO 942241 A NO942241 A NO 942241A NO 942241 A NO942241 A NO 942241A NO 942241 L NO942241 L NO 942241L
Authority
NO
Norway
Prior art keywords
day
bisphosphonate
parathyroid hormone
administered
administration regimen
Prior art date
Application number
NO942241A
Other languages
English (en)
Norwegian (no)
Other versions
NO942241D0 (no
Inventor
Ann Dunbar Geddes
Rogely Waite Boyce
Original Assignee
Procter & Gamble Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble Pharma filed Critical Procter & Gamble Pharma
Publication of NO942241D0 publication Critical patent/NO942241D0/no
Publication of NO942241L publication Critical patent/NO942241L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO942241A 1991-12-17 1994-06-15 Fremgangsmåte for behandling av osteoporose ved behandling av bisfosfonater og parathyreoideahormon NO942241D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80962091A 1991-12-17 1991-12-17
PCT/US1992/010869 WO1993011786A1 (en) 1991-12-17 1992-12-15 Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone

Publications (2)

Publication Number Publication Date
NO942241D0 NO942241D0 (no) 1994-06-15
NO942241L true NO942241L (de) 1994-08-09

Family

ID=25201804

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942241A NO942241D0 (no) 1991-12-17 1994-06-15 Fremgangsmåte for behandling av osteoporose ved behandling av bisfosfonater og parathyreoideahormon

Country Status (18)

Country Link
US (1) US5616560A (de)
EP (1) EP0618805A1 (de)
JP (1) JPH07502507A (de)
AU (2) AU3322593A (de)
BR (1) BR9206941A (de)
CA (1) CA2124792C (de)
CZ (1) CZ282889B6 (de)
FI (1) FI942884A (de)
HU (1) HUT68010A (de)
IL (1) IL104108A (de)
MA (1) MA23079A1 (de)
MX (1) MX9207349A (de)
NO (1) NO942241D0 (de)
NZ (1) NZ246456A (de)
RU (2) RU2112515C1 (de)
SK (1) SK74594A3 (de)
WO (1) WO1993011786A1 (de)
ZA (1) ZA929758B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9206941A (pt) * 1991-12-17 1995-05-02 Procter & Gamble Pharma Métodos para o tratamento da osteoporose usando-se bifosfonatos e hormônio paratireóideo
AU4859493A (en) * 1992-10-09 1994-05-09 Upjohn Company, The Pyrimidine bisphosphonate esters and (alkoxymethylphosphinyl)alkyl phosphonic acids as anti-inflammatories
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
CA2199251A1 (en) * 1994-09-09 1996-03-14 Ann Dunbar Geddes Phosphonates and parathyroid hormone for osteoporosis
KR970705400A (ko) * 1994-09-09 1997-10-09 레이셔 야코버스 코넬리스 골 활성 포스포네이트 및 부갑상선 호르몬을 사용한 골다공증의 치료방법(methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone)
JPH10511095A (ja) * 1994-12-19 1998-10-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド 副甲状腺ホルモン又はその作動薬の低用量継続投与
US5747456A (en) * 1994-12-19 1998-05-05 Beth Israel Deaconess Medical Center Continuous low-dose administration of parathyroid hormone or its agonist
DE69534923T2 (de) * 1994-12-28 2006-11-23 Gador S.A. Anabolische zubereitung für knochenmasse enthaltend olpadronat
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
EP0891779A1 (de) * 1997-06-19 1999-01-20 Roche Diagnostics GmbH Pharmazeutische Kombinationspräparate enthaltend Parathyroidhormon und Calcium- und/oder Phosphatverbindungen
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
EP0922467A3 (de) * 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretische Verabreichung von Medikamenten
EP1123401A1 (de) * 1998-10-22 2001-08-16 The General Hospital Corporation Bioaktive peptide und peptid-derivate von parathyroidhormon (pth) und parathyroidhormon verwandte peptide (pthrp)
WO2000032771A1 (en) 1998-11-30 2000-06-08 The General Hospital Corporation Pth1r and pth3r receptors, methods and uses thereof
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
AU7734800A (en) * 1999-09-29 2001-04-30 General Hospital Corporation, The Polypeptide derivatives of parathyroid hormone (pth)
JP4722375B2 (ja) 2000-06-20 2011-07-13 ノバルティス アーゲー ビホスホネートの投与法
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
KR100491737B1 (ko) * 2001-07-20 2005-05-27 주식회사 한국아이템개발 공기 정화 기능의 모기 퇴치기
WO2003009804A2 (en) 2001-07-23 2003-02-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
DE60233803D1 (de) * 2001-08-17 2009-11-05 Novartis Ag 5-cnac zur oralen verabreichung von parathormonfragmenten
JP2005531532A (ja) * 2002-04-05 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド アレンドロナートおよびビタミンｄ製剤を用いる骨吸収阻害法
KR20060058151A (ko) 2002-05-10 2006-05-29 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
EP2201960A1 (de) * 2003-03-19 2010-06-30 The General Hospital Corporation Konformationseingeschränkte Parathormone mit Alpha-Helix-Stabilisatoren
AR044926A1 (es) * 2003-06-26 2005-10-12 Control Delivery Sys Inc Sistema de suministro de farmacos gelificante in situ
US7910544B2 (en) 2003-07-17 2011-03-22 The General Hospital Corporation Conformationally constrained parthyroid hormone (PTH) analogs
JP2007501241A (ja) * 2003-08-06 2007-01-25 ローディア インコーポレイティド 骨成長を促進する方法
US20050043359A1 (en) * 2003-08-20 2005-02-24 The Procter & Gamble Company Kit for treatment of upper gastrointestinal tract conditions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
AU2006315132A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
JP2009545320A (ja) * 2006-08-04 2009-12-24 ザ ジェネラル ホスピタル コーポレイション 副甲状腺ホルモン（ｐｔｈ）のポリペプチド誘導体
ES2663512T3 (es) * 2007-05-24 2018-04-13 Ablynx N.V. Secuencias de aminoácidos dirigidas contra RANK-L y polipéptidos que comprenden las mismas para el tratamiento de enfermedades y trastornos óseos
BRPI0814962B8 (pt) * 2007-08-01 2021-05-25 Chugai Pharmaceutical Co Ltd métodos in vitro para determinar se um composto candidato é um agonista de longa duração ou de curta duração de um receptor acoplado à proteína g, polipeptídeo, seu uso e composição farmacêutica
EP2509996A1 (de) 2009-12-07 2012-10-17 Michigan Technological University Schwarzbär-parathyroid-hormon und verfahren zur verwendung des schwarzbär-parathyroid-hormons
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
RU2604809C2 (ru) 2010-05-13 2016-12-10 Дзе Дженерал Хоспитал Корпорейшн Аналоги паратиреоидного гормона и их применение
WO2016163886A2 (en) 2015-04-10 2016-10-13 Clues2Cure International B.V. Administration of taurine or an analog thereof for the treatment of nerve cell damage
JP6618139B1 (ja) * 2018-10-29 2019-12-11 旭化成ファーマ株式会社 週２回の頻度でテリパラチド又はその塩を投与することを特徴とする、骨粗鬆症の予防又は治療方法
WO2020090174A1 (ja) 2018-10-29 2020-05-07 旭化成ファーマ株式会社 週２回の頻度でテリパラチド又はその塩を投与することを特徴とする、骨粗鬆症の予防又は治療方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086196A (en) * 1975-03-28 1978-04-25 Armour Pharmaceutical Company Parathyroid hormone
DE3243358A1 (de) * 1982-11-24 1984-05-24 Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch Synthetisches humanes (1-38) parathormon-fragment, verfahren zu seiner herstellung und die verwendung zur behandlung der osteoporose
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
BR9206941A (pt) * 1991-12-17 1995-05-02 Procter & Gamble Pharma Métodos para o tratamento da osteoporose usando-se bifosfonatos e hormônio paratireóideo

Also Published As

Publication number Publication date
CA2124792C (en) 2000-07-04
RU2104699C1 (ru) 1998-02-20
AU3022692A (en) 1993-06-24
CA2124792A1 (en) 1993-06-24
CZ282889B6 (cs) 1997-11-12
WO1993011786A1 (en) 1993-06-24
IL104108A0 (en) 1993-05-13
AU663348B2 (en) 1995-10-05
IL104108A (en) 1999-09-22
RU2112515C1 (ru) 1998-06-10
JPH07502507A (ja) 1995-03-16
MA23079A1 (fr) 1993-07-01
MX9207349A (es) 1993-12-01
AU3322593A (en) 1993-07-19
HUT68010A (en) 1995-05-29
SK74594A3 (en) 1995-01-12
RU94031209A (ru) 1996-07-27
NZ246456A (en) 1997-03-24
FI942884A0 (fi) 1994-06-16
US5616560A (en) 1997-04-01
EP0618805A1 (de) 1994-10-12
NO942241D0 (no) 1994-06-15
ZA929758B (en) 1993-09-10
CZ147794A3 (en) 1994-12-15
FI942884A (fi) 1994-06-16
HU9401798D0 (en) 1994-09-28
BR9206941A (pt) 1995-05-02

Similar Documents

Publication Publication Date Title
NO942241L (de)
RU92004521A (ru) Применение бисфосфонатов и экстракта паращитовидных желез для лечения остеопороза и набор для лечения
IL78342A (en) Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
DE69127470D1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DK0650361T3 (da) Sammensætninger til behandling af arthritis, hvilke sammensætninger indeholder phosphonater og NSAID'er
IS4187A (is) Ný lyfjablanda til inntöku um munn sem inniheldurnýtt magnesíumsalt ómeprasóls, aðferð við framleiðslu hennar og notkun
DK0998288T3 (da) Sammensætninger indeholdende kapasaicin eller kapsaicinanaloge og et lokalbedøvelsesmiddel
RU94046316A (ru) Применение высокоэффективных фосфонатов при изготовлении лекарственных средств для лечения остеопороза
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
Law et al. The effect of calcium hydroxide on deep carious lesions
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
ATE161423T1 (de) Verwendung von phosphinate zur behandlung der osteoporose
CA2294101A1 (en) A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor
DE69420776D1 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
NO945059L (no) Preparater for behandling av artritt inneholdende fosfonater og NSAIDer
NO945058L (no) Anvendelse av fosfonater for behandling av osteoporose
DE69220229D1 (de) Somatotropin zur erhoehung der reproduktiven leistung in rinder
SE8700157D0 (sv) Sett att forhindra kvicksilverforgiftning orsakad av upplosning av kvicksilver ur amalgamplomber samt komposition herfor